Arcutis Biotherapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcutis Biotherapeutics, Inc.
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
Zoryve joins Dermavant's Vtama as a new topical drug with a broad label for plaque psoriasis and offers some points of differentiation, including price.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The firm is planning a US NDA filing after its roflumilast formulation succeeded in a pivotal seborrheic dermatitis study but analysts are keener on a ‘make or break’ approval in psoriasis.
- Topical Delivery
- Drug Delivery